orvepitant (GW 823296) / NeRRe Therap 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  Journal:  Managed care considerations for the treatment of chronic cough. (Pubmed Central) -  Oct 12, 2022   
    These targeted agents may have improved efficacy and safety profiles, helping fill unmet treatment needs. If approved, managed care organizations must develop formulary placement and utilization management criteria based on clinical guideline recommendations, expert opinion, and cost-effectiveness analyses to support the clinically appropriate use of these targeted therapies for best patient outcomes.
  • ||||||||||  orvepitant (GW 823296) / NeRRe Therap
    Enrollment open:  IPF COMFORT: Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) -  Jun 24, 2022   
    P2,  N=88, Recruiting, 
    If approved, managed care organizations must develop formulary placement and utilization management criteria based on clinical guideline recommendations, expert opinion, and cost-effectiveness analyses to support the clinically appropriate use of these targeted therapies for best patient outcomes. Not yet recruiting --> Recruiting
  • ||||||||||  orvepitant (GW 823296) / NeRRe Therap
    Therpeutic Effect of Novel Antipsychotic Drugs Acting at Receptors of Neurotransmitters and Neuropeptides (San Francisco, CA) -  Jun 20, 2022 - Abstract #NDS2022NDS_79;    
    In preclinical studies, the antidepressant effect of orvepitant, an NK1 receptor antagonist, has been demonstrated: this antagonist reaches a complete antagonism of NK1 receptors...The superior therapeutic effect of antidepressant drugs like venlafaxine, a selective noradrenaline and serotonin reuptake inhibitor and bupropion, a selective dopamine and nordrenaline reuptake inhibitor and their adverse effects will be pointed out. Non-pharmacological measures to enhance the antidepressant effect will also be discussed.
  • ||||||||||  orvepitant (GW 823296) / NeRRe, tradipitant (VLY-686) / Vanda, serlopitant (JTS 661) / Menlo Therap
    Review, Journal:  NK-1 Receptor Antagonists and Pruritus: Review of Current Literature. (Pubmed Central) -  Jun 14, 2019   
    For this purpose, a systemic electronic literature search of the PubMed and CINAHL databases, Cochrane Library, and clinicaltrials.gov website was performed. Based on currently available data, it can be concluded that NK-1 inhibitors show significant antipruritic potential for treatment of chronic pruritus in different dermatological conditions, but further studies are needed to establish the best indications and dosage of these drugs.
  • ||||||||||  orvepitant (GW 823296) / NeRRe Therap
    Trial completion:  A Dose-ranging Study of Orvepitant in Patients With Chronic Refractory Cough (clinicaltrials.gov) -  Mar 13, 2019   
    P2,  N=315, Completed, 
    Based on currently available data, it can be concluded that NK-1 inhibitors show significant antipruritic potential for treatment of chronic pruritus in different dermatological conditions, but further studies are needed to establish the best indications and dosage of these drugs. Active, not recruiting --> Completed
  • ||||||||||  orvepitant (GW 823296) / NeRRe Therap
    Trial completion date, Trial primary completion date:  A Dose-ranging Study of Orvepitant in Patients With Chronic Refractory Cough (clinicaltrials.gov) -  Jul 12, 2018   
    P2,  N=244, Recruiting, 
    Recruiting --> Completed Trial completion date: May 2018 --> Dec 2018 | Trial primary completion date: May 2018 --> Dec 2018
  • ||||||||||  orvepitant (GW 823296) / NeRRe Therap
    Enrollment change, Trial primary completion date:  Orvepitant (GW823296) in Adult Post Traumatic Stress Disorder (clinicaltrials.gov) -  Sep 1, 2017   
    P2,  N=132, Completed, 
    Not yet recruiting --> Recruiting N=240 --> 132 | Trial primary completion date: Oct 2010 --> Jun 2010